Acurx Pharmaceuticals, Inc. (ACXP): Nasdaq/NYSE listing notice — Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement

Acurx Pharmaceuticals, Inc.

Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.
Company cautions no assurance that plan will be accepted or compliance regained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Acurx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 25, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less

View on SEC.gov

Browse all listing & compliance notices →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-029370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.